title: Experiences with novel techniques for reduction of stent flow in transjugular intrahepatic portosystemic shunts.
abstract: The transjugular intrahepatic portosystemic shunt (TIPS) may deteriorate liver function and can cause encephalopathy in patients with cirrhosis of the liver. Then reduction of TIPS flow may be required. We here report several attempts to reduce shunt flow in TIPS-induced encephalopathy or liver function impairment with novel techniques. Three patients with cirrhosis of the liver were investigated: Two with severe recurrent encephalopathy and one with impaired liver function following TIPS insertion. Insertion of a reducing stent was ineffective to decrease shunt flow velocity in one patient with severe coagulopathy. Sufficient reduction of shunt flow was achieved by embolizing the space around the hourglass waist of the reducing stent with an occlusion emulsion. Insertion of a conventional stent within the preexisting TIPS with or without additional embolization reduced TIPS flow in the other patients. After reduction of shunt flow encephalopathy improved and liver function returned to the level before TIPS, respectively. During follow-up no occlusion of TIPS was observed. Thus, reduction of shunt flow velocity can be achieved by insertion of an additional stent into a curve-shaped TIPS. Embolization can be helpful to decrease TIPS flow, particularly in patients with severe coagulopathy. Reduction of TIPS flow can correct TIPS-induced complications.
authors.affiliation: Department of Medicine II, University of Munich, Germany.
authors.forename: A L
authors.initials: AL
authors.lastname: Gerbes
authors.forename: T
authors.initials: T
authors.lastname: Waggershauser
authors.forename: J
authors.initials: J
authors.lastname: Holl
authors.forename: V
authors.initials: V
authors.lastname: Gülberg
authors.forename: G
authors.initials: G
authors.lastname: Fischer
authors.forename: M
authors.initials: M
authors.lastname: Reiser
mesh_terms: D001783:Blood Flow Velocity / Q000502:physiology; D003973:Diatrizoate; D004338:Drug Combinations; D004621:Embolization, Therapeutic; D005227:Fatty Acids; D005500:Follow-Up Studies; D006501:Hepatic Encephalopathy / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D019168:Portasystemic Shunt, Transjugular Intrahepatic / Q000295:instrumentation*; D011409:Propylene Glycols; D011859:Radiography; D019233:Retreatment; D015607:Stents; D015028:Zein
chemical_list: D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D003973:Diatrizoate; D015028:Zein; C020481:alcoholic prolamine solution